

**TITLE**

PrHADLIMA™

Adalimumab injection

40 mg in 0.8 mL sterile solution (50 mg/mL), pre-filled syringe for subcuta

PrHADLIMA™

Adalimumab injection

40 mg in 0.8 mL sterile solution (50 mg/mL), auto-injector for subcutan

HADLIMA™ (adalimumab injection) is a biosimilar biologic drug (biosimila

Biological Response Modifier

**HADLIMA™ or HADLIMA™ PushTouch™ (adalimumab injection) treatment supervised by specialist physicians experienced in the diagnosis and tre arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, anky Crohn's disease, ulcerative colitis, adult hidradenitis suppurativa, plaque p and familiar with the HADLIMA™ or HADLIMA™ PushTouch™ efficacy**

**COMPANY NAME AND ADDRESS**

SAMSUNG BIOEPIS  
107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987,  
Republic of Korea

Distributed by:  
Merck Canada Inc.  
Kirkland QC Canada H9H 4M7

**DATE OF INITIAL**

December 20, 2018

**DATE OF REVISION**

December 20, 2019

**CONTROL NUMBER**

123456

## 1. Title Page, page 1